DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
-8.66%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$419M
AUM Growth
+$419M
(-4.7%)
Cap. Flow
+$1.35M
Cap. Flow
% of AUM
0.32%
Top 10 Holdings %
Top 10 Hldgs %
47.79%
Holding
85
New
13
Increased
17
Reduced
18
Closed
2
Top Buys
| 1 |
AtriCure
ATRC
|
$8.38M |
| 2 |
UroGen Pharma
URGN
|
$7.87M |
| 3 |
Biohaven
BHVN
|
$3.47M |
| 4 |
Alkermes
ALKS
|
$2.91M |
| 5 |
SLRN
ACELYRIN
SLRN
|
$2.17M |
Top Sells
| 1 |
Perspective Therapeutics
CATX
|
$28.6M |
| 2 |
Procept Biorobotics
PRCT
|
$2.5M |
| 3 |
Tandem Diabetes Care
TNDM
|
$2.18M |
| 4 |
Ascendis Pharma
ASND
|
$1.57M |
| 5 |
BioNTech
BNTX
|
$1.57M |
Sector Composition
| 1 | Healthcare | 85.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
SPDR S&P Biotech ETF
XBI
$5.07B
| $41.3M | 9.86% | 445,005 +13,790 | +3% | +$1.28M |
|
2
Stereotaxis
STXS
$261M
| $24.9M | 5.95% | 13,680,554 | – | – |
|
3
Merus
MRUS
$4.98B
| $24.2M | 5.79% | 409,445 +30,450 | +8% | +$1.8M |
|
4
Cytokinetics
CYTK
$4.23B
| $21.6M | 5.15% | 398,100 | – | – |
|
5
Revolution Medicines
RVMD
$7.1B
| $19.9M | 4.75% | 511,894 | – | – |
|
6
IDEAYA Biosciences
IDYA
$2.15B
| $14.8M | 3.54% | 422,213 -24,128 | -5% | -$847K |
|
|
7
AtriCure
ATRC
$1.84B
| $14.6M | 3.48% | 639,173 +368,144 | +136% | +$8.38M |
|
8
iShares Biotechnology ETF
IBB
$5.6B
| $14.1M | 3.36% | 102,500 | – | – |
|
9
Syndax Pharmaceuticals
SNDX
$1.41B
| $13.5M | 3.22% | 657,074 -2,500 | -0.4% | -$51.3K |
|
|
BPMC
10
DELISTED
Blueprint Medicines
BPMC
| $11.3M | 2.7% | 104,763 -2,000 | -2% | -$216K |
|
|
11
Ascendis Pharma
ASND
$11.8B
| $11M | 2.64% | 80,972 -11,500 | -12% | -$1.57M |
|
12
Xenon Pharmaceuticals
XENE
$2.98B
| $10.7M | 2.55% | 273,739 | – | – |
|
13
Viking Therapeutics
VKTX
$3.04B
| $10M | 2.4% | 189,117 -5,000 | -3% | -$265K |
|
14
Neurocrine Biosciences
NBIX
$13.8B
| $9.86M | 2.36% | 71,615 | – | – |
|
15
KalVista Pharmaceuticals
KALV
$678M
| $9.51M | 2.27% | 806,973 | – | – |
|
16
Day One Biopharmaceuticals
DAWN
$769M
| $9.18M | 2.19% | 666,463 | – | – |
|
17
Kura Oncology
KURA
$686M
| $8.72M | 2.08% | 423,500 +10,837 | +3% | +$223K |
|
|
18
Tandem Diabetes Care
TNDM
$845M
| $8.23M | 1.97% | 204,208 -54,000 | -21% | -$2.18M |
|
|
MORF
19
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $7.9M | 1.89% | 231,748 | – | – |
|
|
20
UroGen Pharma
URGN
$900M
| $7.87M | 1.88% | +469,000 | New | +$7.87M |
|
|
21
Biohaven
BHVN
$1.63B
| $7.59M | 1.81% | 218,730 +100,000 | +84% | +$3.47M |
|
22
DexCom
DXCM
$29.5B
| $7.43M | 1.78% | 65,552 | – | – |
|
23
Axogen
AXGN
$743M
| $6.78M | 1.62% | 935,894 | – | – |
|
24
Edgewise Therapeutics
EWTX
$1.51B
| $5.23M | 1.25% | 290,197 -16,000 | -5% | -$288K |
|
25
Larimar Therapeutics
LRMR
$310M
| $4.64M | 1.11% | 639,974 -16,399 | -2% | -$119K |
|